Last reviewed · How we verify
Once-daily envarsus XR
Once-daily envarsus XR is a Small molecule drug developed by University of Southern California. It is currently FDA-approved. Also known as: extended releated tacrolimus.
At a glance
| Generic name | Once-daily envarsus XR |
|---|---|
| Also known as | extended releated tacrolimus |
| Sponsor | University of Southern California |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients (PHASE4)
- Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY) (PHASE4)
- Envarsus XR Compared to Immediate Release Tacrolimus (PHASE4)
- PK Assessment of Tacrolimus Exposure Before and After a Switch From Twice Daily Immediate-release (Prograf®) to Once-daily Prolonged Release Tacrolimus (Envarsus®) (PHASE4)
- Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR (PHASE4)
- Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants (PHASE4)
- Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen (PHASE2)
- Extended-Release Tacrolimus Following Liver Transplantation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Once-daily envarsus XR CI brief — competitive landscape report
- Once-daily envarsus XR updates RSS · CI watch RSS
- University of Southern California portfolio CI
Frequently asked questions about Once-daily envarsus XR
What is Once-daily envarsus XR?
Once-daily envarsus XR is a Small molecule drug developed by University of Southern California.
Who makes Once-daily envarsus XR?
Once-daily envarsus XR is developed and marketed by University of Southern California (see full University of Southern California pipeline at /company/university-of-southern-california).
Is Once-daily envarsus XR also known as anything else?
Once-daily envarsus XR is also known as extended releated tacrolimus.
What development phase is Once-daily envarsus XR in?
Once-daily envarsus XR is FDA-approved (marketed).
Related
- Manufacturer: University of Southern California — full pipeline
- Also known as: extended releated tacrolimus
- Compare: Once-daily envarsus XR vs similar drugs
- Pricing: Once-daily envarsus XR cost, discount & access